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& Robert Lober6
We propose a statistical multiscale mapping approach to identify microscopic and molecular 
heterogeneity across a tumor microenvironment using multiparametric MR (mp-MR). Twenty-nine 
patients underwent pre-surgical mp-MR followed by MR-guided stereotactic core biopsy. The locations 
of the biopsy cores were identified in the pre-surgical images using stereotactic bitmaps acquired 
during surgery. Feature matrices mapped the multiparametric voxel values in the vicinity of the biopsy 
cores to the pathologic outcome variables for each patient and logistic regression tested the individual 
and collective predictive power of the MR contrasts. A non-parametric weighted k-nearest neighbor 
classifier evaluated the feature matrices in a leave-one-out cross validation design across patients. 
Resulting class membership probabilities were converted to chi-square statistics to develop full-brain 
parametric maps, implementing Gaussian random field theory to estimate inter-voxel dependencies. 
Corrections for family-wise error rates were performed using Benjamini-Hochberg and random field 
theory, and the resulting accuracies were compared. The combination of all five image contrasts 
correlated with outcome (P < 10−4) for all four microscopic variables. The probabilistic mapping 
method using Benjamini-Hochberg generated statistically significant results (α ≤ 0.05) for three of 
the four dependent variables: (1) IDH1, (2) MGMT, and (3) microvascular proliferation, with an average 
classification accuracy of 0.984 ± 0.02 and an average classification sensitivity of 1.567% ± 0.967. 
The images corrected by random field theory demonstrated improved classification accuracy 
(0.989 ± 0.008) and classification sensitivity (5.967% ± 2.857) compared with Benjamini-Hochberg. 
Microscopic and molecular tumor properties can be assessed with statistical confidence across the brain 
from minimally-invasive, mp-MR.
Emerging targeted therapies interfere with specific molecules that promote tumor growth and infiltration based 
on patient-specific predictive cellular and molecular biomarkers1. However, heterogeneous genomic and phe-
notypic tumor microenvironments contribute to incomplete treatment by targeted therapy and promote tumor 
recurrence via a non-linear branched evolution of the cancer genome2–4. Biopsy is currently the most effective 
method to assess patient-specific tumor biomarkers for targeted therapeutics, but clinical outcomes are limited 
by tumor heterogeneity which cannot be assessed by invasive biopsy alone1. Medical imaging techniques that 
are minimally-invasive and assess cellular and molecular tissue characteristics across the entire tumor bed and 
tumor microenvironment (TME) hold the potential to significantly improve the characterization and treatment 
of aggressive brain tumors5–7.
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Significant efforts are underway to develop tumor heterogeneity mapping techniques using minimally-invasive 
imaging including texture analysis8–10 proton11,12 and hyperpolarized 13C13 spectroscopy; and most recently MR 
fingerprinting14. Generally these methods classify tumor properties at one of two levels: (1) volumetrically, by 
segmenting adjacent voxels together into classes, or (2) on a voxel-wise basis, treating each voxel independently. 
Volumetric segmentation techniques leverage spatial correlations in adjacent voxels that may be associated with 
tumor biology and/or the physical attributes of the acquisition process to improve SNR and classification accu-
racy. However, these improvements are balanced by a decrease in the theoretical spatial resolution of the para-
metric images, ultimately limiting the assessment of heterogeneity. Voxel-wise methods have a theoretical spatial 
resolution on the order of a single voxel, but suffer from significantly increased noise, which may be counteracted 
by the concomitant acquisition of multiple MR signatures. A recent voxel-wise algorithm demonstrated the abil-
ity to map tumor cellularity from three MR contrasts when biopsy findings were localized to the pre-surgical 
images15. Functional Diffusion Maps (fDMs) have also been estimated from ADC maps by identifying biopsy core 
locations on intra-operative computed tomography and post-surgical high resolution 3D anatomical images16. 
Alternatively, MR Fingerprinting (MRF) is a promising voxel-wise approach that has been successfully used to 
parameterize important tumor tissue properties including T1, T2, and M0, as well as physical system properties 
including B0 and B117. There is some emerging evidence that MRF can be used to map functional tissue parame-
ters including perfusion, oxygenation, and microvascular structure18, but the extent to which the MRF technique 
can be applied to functional, cellular, and molecular imaging remains unknown.
Here we propose to map cellular and molecular tumor properties throughout the TME in a voxel-wise manner 
by leveraging the growing dimensionality of clinical MR data. Our approach does not inherently rely on spatial 
correlation information or simulations of various tissue properties for classification. Instead, we hypothesize that 
the dimensionality of MR data alone provides a readily available vehicle to traverse tissue scale. We evaluate our 
hypothesis in three separate sub-steps: Sub-hypothesis 1) significant relationships (α ≤ .0 05) between macro- 
and micro-scale properties can be identified using elementary statistical testing when surgical pathology results 
are localized to the pre-surgical image space; Sub-hypothesis 2) non-parametric machine learning can classify 
microscopic properties from macroscopic images with high accuracy (≥ 95%) when traditional corrections for 
family-wise error rates are employed; and Sub-hypothesis 3) clinically-useful multiscale classification across the 
entire image space can be accomplished when the parametric images are treated as Gaussian random fields.
Experimentally, we developed a data-driven model linking spatially registered core biopsy data to multipar-
ametric MR. We used a diverse patient population consisting of more than 10 different disease classes, making 
the microscopic classifications more difficult but also more generalizable to a clinical population. We performed 
initial statistical evaluations on the model to determine the feasibility of predicting the biopsy findings from 
the MR values alone. We then evaluated the use of non-parametric machine learning to predict four clinically 
relevant properties: IDH1 mutation status, MGMT promoter methylation, cellular necrosis, and microvascu-
lar proliferation. Class membership probabilities output from the machine learning model were converted to 
chi-square statistical estimates using probabilistic distributions of the dependent variables identified a priori. 
The Benjamini-Hochberg algorithm controlled for family-wise error rates (FWER), and the classification accu-
racy and sensitivity of the results were optimized across a single classification tuning parameter. Finally, the 
machine learning model was extended to calculate chi-square (χ2) parametric maps across the entire brain of 
all 29 patients. To improve statistical classification sensitivity in the image domain, we implemented Gaussian 
random field theory (RFT) to estimate the interdependence of voxels and then group statistical findings into 
thresholded clusters. We evaluated the images qualitatively by clinical experts and quantitatively by classification 
accuracy in the biopsy sample volume.
Methods
Study population and model development. The Indiana University Institutional Review Board (IRB) 
reviewed and exempted this retrospective study and waived informed consent under the conditions that all 
patient data would be de-identified upon the completion of patient enrollment. All procedures, methods, and 
experiments performed in this study were carried out in accordance with relevant guidelines and regulations, 
including the HIPAA Privacy Rule and the Declaration of Helsinki. De-identification consisted of removing all 
18 HIPAA Privacy Rule identifiers from images, pathology reports, and clinical data. Accordingly, all dates were 
removed, but age and the difference in days between imaging and biopsy were retained for each patient. This 
study was not listed on ClinicalTrials.gov, and no part of the dataset presented here has been used or published on 
in the past. All source data used in this paper are openly shared with the radiology community for research repli-
cation and further analyses at http://www.iu.edu/~mipl. Inclusion criteria for this study required that the patients 
(1) had previously undergone targeted (stereotactic image-guided) core biopsy of the brain at our institution with 
at least three orthogonal plane images saved showing the location of the core; (2) had completed an MR scan a 
maximum of 60 days prior to biopsy that included at least T1 weighting (T1w), T1 weighting post gadolinium 
injection (T1w-post), T2 weighting (T2w), T2 weighting with fluid attenuated inversion recovery (T2-FLAIR), and 
diffusion weighted imaging (DWI). We specifically did not limit the study to a single tumor type (e.g. glioma) 
to ensure that the non-parametric model could be tested in a clinically-relevant population. Approximately 100 
patients were screened, and 29 met the criteria for enrollment (N = 29). The characteristics of the enrolled popu-
lation are shown in Table 1. All pathology reads and diagnoses were performed by two experienced neuropathol-
ogists, each with more than 10 years’ experience practicing in an academic medical center.
The five MR sequences were the only independent variables used in this analysis – for an overview of the 
acquisition parameters please see Supporting Information – Supplemental Table 1. Approximately 90% of the 
acquisitions were performed at 1.5 T (26 of 29), and approximately 70% of the anatomical sequences used 3D 
readout (101 of 145). All DWI acquisitions used two b-values (0,1000 s/mm2) and 3 orthogonal directions. Fifteen 
(15) of the acquisitions were performed on a Siemens MAGNETOM Aera (Siemens Healthineers, Germany); 
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the remainder were distributed relatively evenly across the GE HDxt (5 acquisitions; GE Healthcare, General 
Electric Company, USA) and various Siemens systems including the Espree (2), Avanto (4), Skyra (2), and Trio 
(1). For post-processing, all images were initially registered to the T1w-post frame-of-reference for each patient. T1w 
was registered using a 12 degree-of-freedom (DOF) transform and minimization of a correlation ratio objective 
function19. T2w, T2-FLAIR, and DWI (B0-only) were registered using a 12 DOF transform and minimization of a 
mutual information objective function20. Apparent diffusion coefficient (ADC) maps were then registered to the 
individual T1w-post reference frame by applying the affine transformation matrix estimated for the DWI B0 images. 
We normalized voxels of each contrast to the mean value of uninvolved white matter determined by a spherical 
Table 1. Subject population characteristics region-of-interest on the T1w-post. The 3-dimensional centroid of the 
biopsy core was identified on the T1w-post for each patient by visually comparing the three-plane neuronavigation 
plans (Fig. 1) to the pre-intervention MR images. We used the size of the biopsy core as reported in the pathology 
report to define a sphere centered at the location of the biopsy needle tip from which the image contrasts were 
extracted. This method ensured the feature matrix and subsequent machine learning model included only those 
voxels representative of biopsied tissues.
Parameter Value
N 29
Sex
F 13/29 (45%)
M 16/29 (55%)
Age (y)
Mean ± standard deviation 56.4 ± 19.3
Range 23–89
Pathology-based diagnosis 29
Glioma 16
WHO Grade IV 7
WHO Grade III 2
WHO Grade II 3
WHO Grade I 4
Metastatic carcinoma 4
Breast 2
Lung 1
Melanoma 1
Diffuse large B-cell lymphoma 2
Schwannoma 1
Reactive changes 2
Abscess 1
Germinoma 1
Demyelination 1
Normal 1
Time between biopsy and imaging (days)
Mean ± standard deviation 9.7 ± 9.1
Range 0–37
Biopsy samples
Mean number of samples taken per 
patient ± standard deviation 3.24 ± 1.8
Mean sample volume (mm3) 4119.5
Table 1. Subject population characteristics *Note – Unless otherwise noted data are specified as number of 
patients.
Figure 1. Example neuronavigation targeting images for Subject 2.
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We extracted the four dependent categorical variables from clinical pathology reports for each patient, 
classifying voxels as IDH1 mutation status positive (IDH1MS+) if the corresponding specimen contained any 
IDH1-R132H-positive cells based on immunohistochemistry, and voxels as MGMT promoter methylation status 
positive (MGMTPMS+) if present based on a methylation-specific PCR-based assay. When applicable, a clinical 
pathologist evaluated several representative microscopic sections for the presence of cellular necrosis (CNEC+) 
and/or microvascular proliferation (MVP+). Because this study was not limited to primary brain tumors, the 
pathologist used their discretion to determine which tests should be applied on an individual patient basis, as a 
standard of care. Importantly, if the physician determined a variable need not be measured for a given patient, we 
classified it as negative for the analysis. These instances were referred to as triage classifications. An overview of 
the four dependent variables across all patient is given in Table 2. The voxel-wise expected distribution for each 
dependant variable (Table 2, row 5) was calculated as the random probability of occurrence based on the number 
of voxels testing positive and the total number of voxels labeled by the tissue specimens. Table 2. Overview of 
the values (positive or negative) of the four dependent variables across the tissue specimen population, and their 
associated voxel-wise probability distributions.
A biostatistician and co-author on this paper (S.C.) guided, oversaw, and reviewed the statistical analyses; an 
overview is given in Fig. 2.
Sub-hypothesis 1: elementary statistical evaluations. First, we calculated the normalized contrast 
values for the independent variables across the entire biopsy sphere for each patient, and combined them into a 
single feature vector mapping the five independent variables to the four outcome variables for each voxel. This 
resulted in a feature matrix of size 147,031 rows x 9 (binary) columns. A binary logistic regression was performed 
for each dependant variable by fitting a maximum-likelihood logit model. The regressions were sample weighted 
by the inverse of the probability of inclusion due to the sampling design to account for class imbalances21. The 
results characterized the overall (combined) predictive power of the five image contrasts for each microscopic 
variable using the Wald χ2 test and McFadden’s pseudo R2 22.
IDH1MS+ MGMTPMS+ CNEC+ MVP+
Samples tested [+, −] [2, 9] [1, 4] [9, 9] [8, 3]
Samples triaged by physician [+, −] [0, 18] [0, 24] [0, 11] [0, 18]
Gross tissue volume (tested + triaged) in mm3 [+, −] [531, 118934.5] [104, 119361.5] [25439.5, 94026] [6865.5, 112600.5]
Voxels (tested + triaged) [+, −] [360, 146661] [93, 146938] [70359, 76672] [3122, 143909]
Voxel-wise expected distribution [+, −] [0.002, 0.998] [0.001, 0.999] [0.479, 0.521] [0.021, 0.979]
Table 2. Overview of the values (positive or negative) of the four dependent variables across the tissue 
specimen population, and their associated voxel-wise probability distributions.
Figure 2. Flowchart of the processing and statistical analysis steps. Endpoints resulting in statistical conclusions 
are outlined in green.
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Sub-hypothesis 2: multiscale classification without spatial information. Next, we developed indi-
vidual training feature matrices (FVi, train) and testing feature matrices (FVi, test) for each patient, i. The FVi, train and 
FVi, test matrices included the following data: each of the 5 normalized MR contrast values in columns 1–5; the 
subject number (i) in column 6; and the binary class flag for IDH1MS+, MGMTPMS+, CNEC+, and MVP+ in col-
umns 7–10, respectively. The rows of FVi, train corresponded to the biopsied voxels across all patients except patient 
i; the rows of FVi, test corresponded to the biopsied voxels for patient i. A set of 116 machine learning experiments 
(29 patients × 4 dependent variables) were then carried out using a leave-one-out design to ensure that in no case 
could data from the same patient be used for both training and testing.
The machine learning classifier was a non-parametric weighted k-nearest neighbor design (wKNN)23 with 
class weights calculated by the inverse Euclidean distance. The only tuning parameter used for classification was 
the number of neighbors, k, included in the class calculations. The classifier output was a 2-element vector for 
each voxel representing the probability of membership in each binary class, calculated as the normalized sum of 
the inverse Euclidean distance. We transformed the probability vectors across the biopsy volume for each patient 
to a chi-square test statistic (χ2) using Pearson’s method24. The statistic compared our predicted class probability 
for each voxel with the background probability calculated for the entire voxel population across all patients. The 
chi-square transform was chosen (i.e. instead of z or t distributions) because the background probabilities could 
be explicitly calculated from the data. A clinical implementation of this algorithm would similarly have access to 
background population probabilities assuming the availability of a robust training dataset. The χ2 values were 
then thresholded to a given α-value using standard statistical transforms. For FWER correction, a p-value thresh-
old was calculated for each patient using the Benjamini-Hochberg procedure25 at an α of 0.05. We calculated a 
confusion matrix for each patient by choosing the class of greatest probability for all voxels that passed the FWER 
correction. The final measure of classification accuracy, ACC(k), was calculated as the mean accuracy across all 29 
confusion matrices, with optimization across the tuning parameter k. The final measure of classification sensitiv-
ity, SENS(k), was calculated as the percent of voxels sampled by biopsy that met the α threshold.
Sub-hypothesis 3: multiscale classification across the image space. χ2 parametric maps of each 
microscopic variable were then calculated as before for every voxel and overlayed on the T1w-post images using the 
tuning parameter that yielded the greatest value of SENS(k) at an ACC(k) ≥ 0.95. Because the images resulted in 
several orders of magnitude more voxels to be classified than in any of the FVi,test vectors, we determined that a 
less conservative FWER correction approach was necessary. As the χ2 maps were smooth statistical fields, we used 
a mature FWER correction technique widely used in functional MRI which first estimates the spatial correlation 
of the statistical image and then identifies clusters of voxels which result in the expected Euler characteristic (EC) 
for a smooth statistical map26–28. We performed both the spatial correlation and EC optimizations using FSL29,30, 
resulting in χ2 parametric images for each dependent variable that controlled FWER at the 5% level.
Results
Study population and model development. The enrolled population had a median age of 59 years 
(max 89, min 23) and had 16 males (55%). The mean difference in time between imaging and biopsy was 9.7 ± 9.1 
days. The biopsy-confirmed diagnoses included: sixteen gliomas (seven Grade IV, two Grade III, three Grade II, 
and four Grade I), four metastatic carcinomas (two breast, one lung, and one melanoma), two diffuse large B-cell 
lymphoma, one schwannoma, two reactive changes, one abscess, one germinoma, one demyelination, and one 
normal. A detailed overview of the enrolled subject population and demographics is given in Table 1.
Sub-hypothesis 1: elementary statistical evaluations. The combination of all five image contrasts 
was found to be significantly correlated with outcome (P < 10−4) for all four microscopic variables (Table 3). 
IDH1MS+ had the greatest likelihood with a pseudo R2 of 0.26, followed by MGMTPMS+ (0.25), CNEC+ (0.22), 
and MVP+ (0.07). For a complete breakdown of the prediction results by individual image contrast, please see 
Supporting Information – Supplemental Table 2.
Figure 3 shows the parameter estimates (regression coefficients), demonstrating that characteristic pat-
terns of the logits across the five predictors exist for each microscopic variable, even when accounting for the 
robust standard errors. Of note, IDH1MS+ and MGMTPMS+ exhibited strong negative correlations with T1w, and 
MGMTPMS+ also displayed a large negative correlation with ADC. CNEC+ demonstrated a strong positive corre-
lation with T1w, while IDH1MS+ has a strong positive relationship with T2-FLAIR. These initial findings provided 
a statistical foundation upon which our hypothesis could then be tested using the previously described machine 
learning techniques.
Sub-hypothesis 2: multiscale classification without spatial information. The results of the 
machine learning optimization procedure are shown in Fig. 4. Accuracy and the number of statistically signif-
icant voxels are shown in black and blue, respectively. The plots demonstrate that the tuning parameter k has a 
Outcome Observations Wald χ2 P > χ2 Pseudo R2
IDH1MS+ 147,031 18,520.37 10−4 0.2637
MGMTPMS+ 147,031 8437.73 10−4 0.2455
CNEC+ 147,031 22,245.20 10−4 0.2180
MVP+ 147,031 17,136.48 10−4 0.0661
Table 3. Overall prediction results of the combined (5) image contrasts from binary logistic regression analyses.
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large effect on the number of voxels which pass the FWER correction, and thus, indirectly, the overall accuracy 
calculation. There was similar classification behavior between IDH1MS+ and MGMTPMS+, in which classification 
accuracy generally increased with k, and then plateaued as the number of significant voxels began to decrease. 
No voxels passed the FWER correction for cellular necrosis at any value of k that was tested. The classification 
accuracy of MVP had an approximately linear relationship with k, while the number of voxels passing the FWER 
threshold had an approximately inverse linear dependence on k.
From the optimization plots, we chose a tuning parameter that maximized the accuracy and the number of 
voxels that passed the significance threshold. In keeping with our α threshold of 0.05, we limited the minimum 
acceptable classification accuracy to be 0.95; thus, the optimal tuning parameter, kopt, was that which maximized 
SENS(k) in the condition that ACC(k) ≥ 0.95. Table 4 shows the optimized tuning parameter and classification 
results for the four microscopic variables. The values of kopt for each outcome are also shown as vertical green bars 
in Fig. 4.
Of the 3 variables that had significant findings (IDH1, MGMT, MVP) the average classification accuracy was 
0.984 ± 0.02 and the average classification sensitivity was 1.567% ± 0.967. Optimal classification results for the 
molecular markers IDH1MS+ and MGMTPMS+ were similar, both yielding an ACC(k) of 1.0 and a SENS(k) slightly 
greater than 2%. The optimal ACC(k) of MVP+ was 0.951 with a SENS(k) of 0.2%. These results confirmed our 
hypothesis that multiscale classification could be performed without spatial information. However, the low num-
ber of voxels passing the correction threshold supported further evaluation of a FWER-correction technique that 
was more sensitive to classification.
Sub-hypothesis 3: multiscale classification across the image space. Example images corrected by 
RFT using kopt for IDH1MS+, MGMTPMS+, and MVP+ are shown in Fig. 5 for 3 exemplary patients. Images for 4 
Figure 3. Regression coefficients for each microscopic variable across the 5 image contrasts. Error bars 
represent robust standard errors.
Figure 4. Accuracy (black; left vertical axis) and number of significant voxels (blue; right vertical axis) vs. the 
wKNN tuning parameter k. The optimal tuning parameter value (kopt) maximized the number of significant 
voxels when α ≤ .0 05. kopt is indicated by a vertical green line for each outcome variable.
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additional patients are given in Supplemental Materials – Supp. Figure I. In Fig. 5, the biopsy site for each patient is 
indicated with a yellow crosshair on the zoomed-in χ2RFT maps (2nd row), and the original uncorrected probability 
maps generated by the machine learning model are shown in row 3.
Qualitatively the images demonstrate smooth statistical fields that are well localized to the tumor bed and 
TME. The quantitative classification results based on the χ2RFT-corrected images are shown in Table 5. RFT 
demonstrated improved average classification accuracy (0.989 ± 0.008) and sensitivity (5.967%  ± 2.857) com-
pared with Benjamini-Hochberg. Notably, SENS(k) for MVP+ increased to 9.9% using RFT compared with 0.2% 
with Benjamini-Hochberg.
Figure 6 shows an example GBM subject had significant results for all 3 outcome variables that nearly covered 
the entire TME (Subject 8). The 5 predictor contrasts are shown along the left side of the image zoomed-in on the 
tumor bed and TME. The colormaps are windowed from 0 to the maximum χ2RFT statistic (right side colorbars). 
Potential significant findings for MVP+ outside the T2-FLAIR abnormality (3 red speckles frontal and medial to 
the tumor) may hold important information related to microscopic disease spread.
Discussion and Conclusions
Cellular and molecular heterogeneity is a significant driver of brain tumor morbidity that cannot be assessed by 
biopsy alone. This paper demonstrated three different methods to predict microscopic cellular and molecular 
properties of brain tumors from macroscopic, minimally-invasive clinical images. Elementary statistical evalua-
tions demonstrated that significant relationships between the macroscopic and microscopic variables of interest 
did exist. Machine learning combined with a conservative correction for family-wise error rates was able to pre-
dict cellular and molecular properties with high accuracy but limited classification sensitivity (0.2–2.3%) for three 
of the four outcome variables. When spatial correlations across voxels were taken into account using Gaussian 
random field theory, high accuracy was retained with a significant increase in classification sensitivity (3.2–9.9%). 
The images generated by random field theory demonstrated acceptable noise and spatial resolution properties for 
clinical interpretation. Taken together, our results show that in vivo microscopic and even genomic mapping of 
human brain tumors may be clinically possible in the near future.
The near-term implication of our findings is that researchers and clinicians utilizing machine learning to 
predict tumor heterogeneity should consider dimensionality to be one potential vehicle by which in vivo imaging 
signatures may be used to traverse scale. The rapid expansion of anatomical and functional MR sequences and 
the growing availability of hybrid imaging systems only serve to enhance this opportunity. The long-term impli-
cations of our findings are that it may be possible to map cellular and molecular tumor properties across both 
space and time during treatment, allowing for highly personalized treatment strategies that are not currently pos-
sible. For example, MGMT promoter methylation status can vary across the tumor bed and microenvironment31 
making treatment planning challenging. Patients who are determined by surgical biopsy to have MGMTPMS+ are 
expected to demonstrate good response to standard of care treatment with concomitant and adjuvant radiation 
therapy and chemotherapy with temozolomide32, although this is almost always followed by relapse and eventual 
death. A subset of these patients are expected to also have undiagnosed MGMTPMS- properties, and thus may 
benefit from experimental personalized therapies33. The ability to map MGMT promotor methylation status with 
a minimally-invasive in vivo probe would allow for better treatment selection and drug combinations than is 
currently possible.
This study provides initial evidence in support of our hypothesis; however, there are significant limitations 
on the generalizability of our findings due to our study design. First, the retrospective design used in this paper 
did not allow for standardization of the immunohistochemical and molecular tests used across patients. This 
drawback required our analysis to rely on the clinical expertise of the pathology physicians in determining which 
tests were required at the individual patient level. Furthermore more comprehensive genomic evaluations (i.e. 
genome-wide association) could have been conducted to identify other predictor-outcome relationships than the 
four we investigated. The MR sequence parameters used for the five predictor variables varied across patients and 
locations which may have diminished their individual and collective effect sizes. The number of MR sequences 
was limited to 5, although many other sequences could have been used including perfusion imaging, chemi-
cal exchange saturation transfer, and MR spectroscopy. The localization procedure used to identify voxels that 
underwent biopsy did not always use the same image, the same image contrast, or even the image modality as the 
image used during biopsy. For example, several biopsies used a recent head CT for stereotactic guidance. Thus, 
the accuracy of the localization procedure was highly dependent on the ability of the human operator to map the 
biopsy location based on anatomical structures and spatial features. Finally, although the diversity of our patient 
cohort was clinically relevant, it very likely weakened our control over the experimental variables and ultimately 
reduced our statistical effect sizes compared with a highly controlled study focused on a single tumor or tissue 
Microscopic 
variable kopt ACC(k)
# of significant 
voxels SENS(k) (%)
IDH1MS+ 800 1.0 4197 2.2
MGMTPMS+ 700 1.0 4399 2.3
CNEC+ N/A 0.0 0 0
MVP+ 3000 0.951 405 0.2
Table 4. Optimized results from the leave-one-out machine learning classification using Benjamini-Hochberg 
correction without spatial correlation information.
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type. However, the ubiquitous drawback of highly-controlled, single-disease radiomics studies is a failure to gen-
eralize to a clinically-relevant patient population34,35.
The poor voxel sensitivity found in this study represents a challenge for future clinical implementations of this 
method. Voxel sensitivity is directly related to the statistical threshold generated by RFT and thus is also linearly 
related to χ2RFT. Three of the four expected distributions calculated from our data had a positive background 
Figure 5. Results of the statistical mapping procedure for 4 select patients, with the location of the biopsy 
marked with a yellow plus sign. In all cases the χ2 image with random field theory correction dramatically 
reduces the number of false positive findings and demonstrates smooth noise properties across space.
Microscopic 
variable kopt ACC(k)
# of significant 
voxels SENS (k) (%)
IDH1MS+ 800 1.0 4732 3.2
MGMTPMS+ 700 0.987 7096 4.8
CNEC+ N/A 0.0 0 0
MVP+ 3000 0.982 14610 9.9
Table 5. Optimized results from the leave-one-out machine learning classification using random field theory 
correction including spatial correlation information.
Figure 6. Extensive visualization of statistical confidence ROI’s mapping genomic and cellular heterogeneity in 
a GBM patient.
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probability of <3%, effectively limiting sensitivity to those voxels with very high classification confidence. We 
believe the background probabilities were primarily limited by the small and heterogeneous biopsy population, 
and we expect a prospectively designed study that could control for the somatic and genomic tests performed 
across all patients, as well as the distribution of tumor and non-tumor types included, would yield far more accu-
rate background probabilities and significantly increase voxel sensitivity.
In summary, we have demonstrated statistical relationships between routine multiparametric imaging sig-
natures and underlying cellular and molecular properties of brain tumors. We have applied advanced statistical 
methods to correct for the family-wise error rate problem associated with whole-brain statistical parametric 
mapping, and have shown that the results have strong agreement with surgical biopsy. These results imply that 
cellular and molecular mapping of tumor heterogeneity from minimally-invasive images may be possible in the 
near future.
Data availability
The datasets generated during and/or analyzed during the current study are available in the MIPL Data and Code 
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